Reaction Biology
Reaction BiologyA US-headquartered global CRO offering comprehensive services from drug discovery research to non-clinical developmentWe offer in-house contract research services, including biochemical assays such as kinase assays, cell-based assays, pharmacology, toxicology, and bioassays.
Features of Reaction Biology's preclinical contract services
Evaluate candidate compounds with comprehensive kinase assays
Reaction BiologyCRO with strengths in kinase drug discovery, we can evaluate the activity and selectivity of candidate compounds using a broad panel targeting the human kinome. We support everything from single-target IC50 measurements to multi-kinase profiling and library screening. By utilizing radioactive assays such as HotSpot™ and ³³PanQinase™, we directly measure the catalytic activity of kinases.
GLP-compliant toxicity testing and GMP bioassays
Non-clinical toxicity evaluation compliant with GLPIt also supports these requirements, and the facility in Heidelberg, Germany, conducts testing based on GLP toxicology and OECD guidelines. The facility also offers GMP potency assays and functional bioassays. With GLP/GMP-certified facilities, we support the efficacy and safety evaluation and quality control of biopharmaceuticals.
We support everything from early drug discovery to evaluations with IND applications in mind.
Not only biochemical assays, but alsocell-based assays, in vivo pharmacology, PK/PD, safety pharmacologyNon-clinical evaluations combining these are available. With multiple research facilities in the United States and Germany, we have accumulated a track record of research that has led to IND filings. In addition to GLP/GMP-compliant services, we also offer analytical support geared toward IND/CTA, making it possible to support you from candidate compound selection through the transition to the development stage.
An example of a disease model owned by Reaction Biology
At Reaction Biology,In vivo efficacy evaluation models centered on the oncology field. The Hershey facility supports tumor models such as xenograft, syngeneic, and orthotopic. The Freiburg facility also conducts evaluations using in vivo efficacy and immuno-oncology models.
Reaction Biology preclinical study cases
3D cell panel evaluation of MEK inhibitors
At Reaction Biology,3D ProLiFiler™ Spheroid Cancer Cell PanelWe have published a case study evaluating MEK inhibitors using . Comparing the drug action between 2D culture and 3D spheroids, the MEK inhibitors used clinically showed higher activity in the 3D environment. This is an example of candidate compound evaluation that takes into account the three-dimensional cellular environment.
Reaction Biology corporate information
Japanese
